Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series
about
The search for novel analgesics: targets and mechanismsClinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeysHeteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptorsStandard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonistsReceptor heteromerization and drug discovery.Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapesBuilding a new conceptual framework for receptor heteromersOpioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesicsOpioid receptor trafficking and interaction in nociceptorsAntibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and functionOpioid receptors: toward separation of analgesic from undesirable effectsOpioid receptor heteromers in analgesiaAnti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonismStructure-guided development of heterodimer-selective GPCR ligandsRequirements and ontology for a G protein-coupled receptor oligomerization knowledge base.Cannabinoid-opioid interactions during neuropathic pain and analgesia.Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.Bi- or multifunctional opioid peptide drugs.Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor.Opioid-receptor-heteromer-specific trafficking and pharmacology.Role of antibodies in developing drugs that target G-protein-coupled receptor dimers.Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.The year in G protein-coupled receptor research.Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects.N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromersDesign strategies for bivalent ligands targeting GPCRs.Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.Mu and delta opioid receptors on nociceptors attenuate mechanical hyperalgesia in rat.Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.Discovery of GPCR ligands for probing signal transduction pathways.Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.In vivo opioid receptor heteromerization: where do we stand?
P2860
Q24288817-CDD22BFB-5350-47EC-84D1-54D8807F13ECQ24597777-790A9093-DFC5-48C4-A4FA-9F2F2E592821Q24630645-DA119D5E-967F-47A0-8B89-D5D53D28A1F5Q24630886-D62A4211-3778-4333-BB3B-DBA07BCD7926Q24631212-E19F52B4-0864-4BDF-8B84-F76AF4D647E2Q24631740-14D3F462-FBE4-466B-AD23-37CBA1BACD3CQ24633877-32D8A5B8-690E-4FCF-94E9-ABF157348B61Q24644975-70D5CC8F-6D97-4615-8D7B-1F5B7B60B9C3Q24647687-DA6F255B-DD73-4BE8-94D7-D2C1E386326FQ26822251-E598C61A-3681-4A20-A8BD-35ECE3A7B86DQ26992192-0AFEC421-4584-4BD3-BE3C-B290CE1429EFQ27002925-198B01E8-717C-4862-BAF2-97E8CEC8B521Q27004306-1B3E16E5-1426-4E9B-879F-BD1AD5531254Q28488120-350B61EF-44C5-489C-8090-C84BA2BF7DA1Q28828634-8F0DE03F-C07C-48B2-89B0-A9EE9610060FQ33286209-957D91B7-5474-409C-9BA7-ACCE6ADEC1B0Q33637224-E2D219D9-D204-4637-9180-1BE833056FF9Q33693780-8B9C1C16-865B-4D1B-BFF8-DDE8482C7738Q33767037-E19E6B76-8F91-4BA3-83DB-F96190B85B84Q33767121-9489CA4A-CE3B-4E09-9F29-5E5DE61367FEQ33807778-78F8014E-23FE-4DB9-8A24-4B5DBD706E0DQ33978499-32182E05-9615-4765-9325-8815BD21AE94Q34051430-26230B5C-10D0-4E91-B70E-201EAF7CB890Q34061067-7BCAD45E-5E4F-4ACE-B10B-800AF0E67F2EQ34077604-C40A555A-5C23-45EA-ADC4-3EEA13482756Q34088801-3D2B0290-1832-47B6-84F3-70A85A6D23B4Q34145241-F23C0928-0989-4F2A-96FF-561544627106Q34169318-00F98C3C-1BE3-4842-8AF6-44657A6A997EQ34180510-D1B26C8E-DF4B-43DE-89F3-19BC0E9AFA3DQ34191032-7D066ED4-FE11-4EF7-8E4D-C65D21DF3B1DQ34209429-BE2982CB-C1DB-4B29-B5E3-81948EAC4A6AQ34354902-7D0DFD1D-80A2-4600-9551-792136944487Q34424009-FB52BEEA-5459-4169-839F-89CE206BB245Q34497517-3FB19AFA-C64D-4FBD-9334-145E603B7D13Q34517465-7C5D5349-A30F-488D-B9C0-B9250B8EBA8AQ34524896-39E4C344-7DFE-4AED-8071-C6845AA5F87AQ34550143-C3BC82DD-D9B8-434F-B1F3-60C57B00B23CQ34582707-528A8FF2-6B0B-4025-BB38-02E168B7507FQ34939624-8BBF7B54-C89B-468C-B40E-158210BA0503Q34939677-3DADC2EF-B1CB-4F0B-93C7-33E809C68DCD
P2860
Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@ast
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@en
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@nl
type
label
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@ast
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@en
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@nl
prefLabel
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@ast
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@en
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@nl
P2093
P2860
P356
P1476
Opioid-induced tolerance and d ...... es in a bivalent ligand series
@en
P2093
Chris L Etienne
David J Daniels
Natalie R Lenard
Philip S Portoghese
Sandra C Roerig
P2860
P304
19208-19213
P356
10.1073/PNAS.0506627102
P407
P50
P577
2005-12-19T00:00:00Z